FDA grants orphan-drug status for skin-disease treatment

07/29/2008 | Sydney Morning Herald (Australia), The

The FDA granted orphan-drug designation to Clinuvel Pharmaceuticals' afamelanotide as a treatment for erythropoietic porphyrias, a rare genetic disorder common in fair-skinned people. The orphan-drug status is a first for Clinuvel, which is developing afamelanotide to treat patients with ultraviolet-related skin diseases.

View Full Article in:

Sydney Morning Herald (Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ